As outlined in Figure 2, preoperative assessment includes confirmation of AD pathology by ≥ 2 abnormal core biomarkers—for example, low CSF/plasma Aβ42 or reduced Aβ42/40 ratio, elevated phosphorylated tau (p‐tau), and/or positive amyloid positron emission tomography (PET)—together with standardized cognitive staging using MMSE, Montreal Cognitive Assessment (MoCA), CDR, and Alzheimer's Disease Assessment Scale Cognitive subscale. This evidence concerns the gene MAPT and Alzheimer disease.